AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00290940
Drug: metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00290940
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00444158
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00975975
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab given 1 time on Day +7 or Day +9.
Trial: NCT01100177
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 37.5mg/m2/d
Trial: NCT02419157
Drug: Selective enamel etching with 36% phosphoric acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etch: selective 36% phosphoric acid enamel etching
Trial: NCT02419157
Drug: No selective enamel etching with 36% phosphoric acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-etch: without phosphoric acid selective enamel etching
Trial: NCT04409964
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
Trial: NCT04409964
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
Trial: NCT01259713
Drug: Liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
Trial: NCT01732393
Drug: oral quercetin capsules
RxNorm normalized name: quercetin Oral Capsule
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
Trial: NCT00512135
Drug: IncobotulinumtoxinA (Xeomin) (20 units)
RxNorm normalized name: incobotulinumtoxinA 100 UNT [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
Trial: NCT01800877
Drug: Vasopressors
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004010
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004010
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00822029
Drug: FOSAMAX
RxNorm normalized name: Fosamax
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient receiving one tablet (oral use) 70 mg Fosamax by week
Trial: NCT01492881
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 400mg, taken days 4 through 11 of each cycle.
Trial: NCT01492881
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
Trial: NCT02246998
Drug: STB
RxNorm normalized name: STB
DrugBank: Steviolbioside (DB12434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
Trial: NCT02246998
Drug: TVD
RxNorm normalized name: Tenofovir disoproxil fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200/300 mg FDC tablet administered orally once daily with food
Trial: NCT02246998
Drug: ATR
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
Trial: NCT02246998
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsule administered orally once daily with food
Trial: NCT02246998
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
Trial: NCT01601808
Drug: Caprelsa (vandetanib)
RxNorm normalized name: Caprelsa
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally once a daily, continuously throughout the study.
Trial: NCT03070730
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droxidopa: 100 mg or 300 mg t.i.d
Trial: NCT03070730
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol: 50 mg Q.D.
Trial: NCT01191944
Drug: pramipexole immediate release tablet
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.375mg-4.5mg(daily dose), three times a day
Trial: NCT02243852
Drug: Growth Hormone Replacement Therapy
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
Trial: NCT01191944
Drug: pramipexole extended release tablet
RxNorm normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.375mg-4.5mg, once a day
Trial: NCT03946358
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity.
Trial: NCT03946358
Drug: UCPVax
RxNorm normalized name: UCPVax
DrugBank: UCPVax (DB17509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5).
Trial: NCT00103220
Drug: SJG-136
RxNorm normalized name: SJG-136
DrugBank: SJG-136 (DB11965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02954991
Drug: Glesatinib
RxNorm normalized name: Glesatinib
DrugBank: Glesatinib (DB06302)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Trial: NCT02954991
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Trial: NCT02954991
Drug: Mocetinostat
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat is an HDAC inhibitor.
Trial: NCT02954991
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Trial: NCT05665985
Drug: Moringa Oleifera
RxNorm normalized name: Moringa Oleifera
DrugBank: Moringa oleifera leaf (DB14362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
Trial: NCT00004179
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004179
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01343082
Drug: DE-111 ophthalmic solution
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01982916
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00519805
Drug: dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044044
Drug: Lurasidone 20 mg
RxNorm normalized name: lurasidone 20 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 20mg/day tablets
Trial: NCT00044044
Drug: Lurasidone 40mg
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 40mg/day tablets
Trial: NCT00044044
Drug: Lurasidone 80 mg
RxNorm normalized name: lurasidone 80 mg oral tablet
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 80mg/day - 2 40mg tablets
Trial: NCT00044044
Drug: Haloperidol 10mg
RxNorm normalized name: HALOPERIDOL 10MG TAB
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol 10mg/day tablets
Trial: NCT00455858
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
Trial: NCT04467450
Drug: botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
Trial: NCT04467450
Drug: Methyl Prednisolonate
RxNorm normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
Trial: NCT02257697
Drug: Mizoribine (MZR)
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00997204
Drug: Icatibant
RxNorm normalized name: Icatibant
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single subcutaneous injection of icatibant, 30 mg
Trial: NCT00154869
Drug: Peginterferon Alfa-2a plus Ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02943135
Drug: lidocaine in-situ gel
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine in-situ gel
Trial: NCT01391377
Drug: Niacin/Laropiprant combination
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
Trial: NCT01391377
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02010385
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02010385
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02417246
Drug: brand name metoprolol ER
RxNorm normalized name: metoprolol Extended Release Oral Capsule
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This medication will be taken for 7 to 28 days
Trial: NCT04483479
Drug: Active Investigational Treatment ENT-01
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
Trial: NCT00053131
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00053131
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00723775
Drug: GSK706769 & KALETRA
DrugBank: Kale (DB14564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK706769 alone and GSK706769 + Kaletra
Trial: NCT00890630
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
Trial: NCT00787332
Drug: Desirudin or Argatroban®
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desirudin 15mg SC Argatroban® IV dosing per Package Insert
Trial: NCT01001494
Drug: Aclidinium bromide 200 μg bid
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
Trial: NCT01001494
Drug: Aclidinium bromide 400 μg bid
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
Trial: NCT00317239
Drug: Ferrous Sulfate tablets
RxNorm normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg/TID x 8 weeks
Trial: NCT00317239
Drug: Ferric Carboxymaltose (FCM)
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
Trial: NCT02065466
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02065466
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02065466
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00406029
Drug: Preladenant
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg BID capsules
Trial: NCT00406029
Drug: Preladenant
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg BID capsules
Trial: NCT00406029
Drug: Preladenant
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg BID capsules
Trial: NCT00406029
Drug: Preladenant
RxNorm normalized name: Preladenant
DrugBank: Preladenant (DB11864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BID capsules
Trial: NCT00406029
Drug: L-dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
Trial: NCT03512340
Drug: SRF231
RxNorm normalized name: Immunoglobulin igg4, anti-(human cd47) (human monoclonal srf231 .gamma.4-chain), disulfide with human monoclonal srf231 .kappa.-chain, dimer
DrugBank: Urabrelimab (DB17209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
Trial: NCT00351884
Drug: Vildagliptin AM
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03283137
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
Trial: NCT03078101
Drug: Empagliflozin 10 MG [Jardiance]
RxNorm normalized name: empagliflozin 10 MG [Jardiance]
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered orally once daily
Trial: NCT00294593
Drug: folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03307447
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 300 mg subcutaneous injection
Trial: NCT00351884
Drug: vildagliptin pm
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03761264
Drug: Pulpdent
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
Trial: NCT03836638
Drug: 30 Units of botulinum toxin
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 30 Units of botulinum toxin to upper face
Trial: NCT03836638
Drug: 50 Units of botulinum toxin
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 50 Units of botulinum toxin to upper face
Trial: NCT01100021
Drug: Tamsulosin and avanafil
RxNorm normalized name: tamsulosin and dutasteride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
Trial: NCT01100021
Drug: Doxazosin and avanafil
RxNorm normalized name: Avanafil
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
Trial: NCT00000530
Drug: nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006452
Drug: motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01399346
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Application of 18 IU insulin aspart as one bolus at one injection site
Trial: NCT01399346
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
Trial: NCT00703807
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
Trial: NCT04211545
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole
Trial: NCT04211545
Drug: CC-92480
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-92480
Trial: NCT01556633
Drug: Tamiflu (oseltamivir)
RxNorm normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Tamiflu in volunteers on dialysis
Trial: NCT01556633
Drug: Tamiflu (oseltamivir)
RxNorm normalized name: oseltamivir Oral Suspension [Tamiflu]
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
Trial: NCT03336840
Drug: Metformin tablets
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal